Table 2.
Cell line | Contr | 60 nM VFL | Equitoxic conc. VRL | 150 nM VFL | Equitoxic conc. VRL |
% G1 | |||||
ECV304 | 39.1 ± 1.9 | 36.3 ± 2.2 | (10 nM) 38.6 ± 2.8 | 15.0 ± 3.4a | (30 nM) 10.1 ± 1.6a |
CAL-27 | 56.4 ± 1.7 | 19.0 ± 1.0a | (10 nM) 19.0 ± 3.4a | 9.2 ± 1.1a | (30 nM) 8.1 ± 1.5a |
MCF-7 | 50.3 ± 1.5 | 19.1 ± 2.3a | (8 nM) 18.0 ± 1.7a | 11.3 ± 3.1a | (20 nM) 10.9 ± 1.8a |
H292 | 56.5 ± 0.9 | 39.3 ± 2.4a | (15 nM) 25.6 ± 3.0a * | 15.0 ± 3.0a | (40 nM) 9.3 ± 2.6a |
% S | |||||
ECV304 | 38.6 ± 1.6 | 44.1 ± 2.9 | (10 nM) 37.1 ± 1.6 | 26.4 ± 3.2a | (30 nM) 17.4 ± 1.7a |
CAL-27 | 25.0 ± 1.1 | 33.3 ± 2.4 | (10 nM) 31.0 ± 3.1 | 14.9 ± 1.9a | (30 nM) 18.8 ± 2.6 |
MCF-7 | 26.2 ± 1.1 | 26.4 ± 1.4 | (8 nM) 32.1 ± 2.0 | 29.7 ± 2.2 | (20 nM) 32.1 ± 2.1a |
H292 | 23.4 ± 0.5 | 23.5 ± 1.0 | (15 nM) 20.0 ± 2.8 | 23.8 ± 2.3 | (40 nM) 18.2 ± 1.8a |
% G2/M | |||||
ECV304 | 20.2 ± 1.0 | 19.2 ± 1.0 | (10 nM) 19.6 ± 2.8 | 50.2 ± 1.7a | (30 nM) 62.5 ± 2.9a * |
CAL-27 | 16.1 ± 0.7 | 30.4 ± 3.9a | (10 nM) 32.8 ± 5.0a | 55.4 ± 3.3a | (30 nM) 53.7 ± 2.4a |
MCF-7 | 20.3 ± 0.8 | 47.2 ± 6.1a | (8 nM) 43.9 ± 1.6a | 52.5 ± 4.7a | (20 nM) 52.2 ± 1.2a |
H292 | 17.8 ± 1.0 | 28.6 ± 1.3a | (15 nM) 50.2 ± 5.0a * | 53.2 ± 6.8a | (40 nM) 65.9 ± 5.0a |
Percentages of cells in the G1, S and G2/M phase of the cell cycle: after 24 h incubation with equitoxic concentrations of VRL and VFL; mean ± standard error.
a p < 0.05 compared to control
* p < 0.05 compared to the equitoxic concentration of VFL